Los Angeles Capital Management LLC Raises Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Los Angeles Capital Management LLC increased its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 54.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 103,005 shares of the company’s stock after buying an additional 36,240 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Stoke Therapeutics were worth $1,266,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Lynx1 Capital Management LP increased its stake in shares of Stoke Therapeutics by 40.3% in the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after acquiring an additional 1,488,371 shares during the period. Redmile Group LLC grew its position in Stoke Therapeutics by 93.2% during the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock worth $68,486,000 after purchasing an additional 2,447,543 shares during the period. Baker BROS. Advisors LP raised its stake in shares of Stoke Therapeutics by 65.9% during the 1st quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock valued at $45,474,000 after buying an additional 1,338,309 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Stoke Therapeutics by 4.1% in the 1st quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock valued at $23,160,000 after buying an additional 67,052 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Stoke Therapeutics in the second quarter worth about $19,835,000.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $20.83.

Insider Activity

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the business’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The trade was a 17.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Trading Up 0.1 %

Shares of Stoke Therapeutics stock opened at $13.92 on Friday. The firm’s 50-day moving average price is $13.14 and its 200 day moving average price is $13.77. Stoke Therapeutics, Inc. has a twelve month low of $3.77 and a twelve month high of $17.58. The firm has a market capitalization of $737.30 million, a PE ratio of -6.72 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.